Welcome to our dedicated page for Opthea American Depositary Shares news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea American Depositary Shares stock.
Opthea Limited (symbol: OPT) is a pioneering Australian biotechnology company dedicated to developing innovative biologic therapies for eye diseases. With a strong focus on medical technology and healthcare, Opthea's primary mission is to address unmet medical needs through advanced therapeutic solutions.
Opthea's flagship product, OPT-302, is a groundbreaking biologic treatment designed to inhibit VEGF-C and VEGF-D, which are critical factors in abnormal blood vessel growth and leakage. These mechanisms are commonly associated with eye conditions such as wet age-related macular degeneration (wet AMD). Currently, OPT-302 is undergoing a Phase 1/2a clinical trial to evaluate its safety and efficacy in patients suffering from wet AMD, marking a significant milestone in the company's development pipeline.
The company's robust intellectual property portfolio underpins its research and development efforts, covering essential targets like VEGF-C, VEGF-D, and VEGF Receptor-3. These assets form the foundation of Opthea's strategy to develop advanced treatments aimed at reducing vascular leakage and managing diseases linked to blood and lymphatic vessel growth.
Recent achievements underscore Opthea's commitment to advancing its clinical programs. The company has launched a fully underwritten Retail Entitlement Offer, inviting eligible retail shareholders in Australia and New Zealand to participate. This initiative is part of Opthea's broader strategy to secure funding and support the continued development of OPT-302.
Participants in the Placement and Entitlement Offer will receive new options, each exercisable at A$0.80, set to expire on 31 August 2025. These options are expected to be quoted on the ASX, providing additional investment opportunities for shareholders.
Investment in biotechnology firms like Opthea entails inherent risks, including the lengthy clinical trial process, patent protection uncertainties, and rapid technological advancements. However, Opthea's focused approach and strategic partnerships position it as a promising player in the biotech space. For detailed information on participation and investment opportunities, refer to the Prospectus available on the ASX website and Opthea's official site.
For more updates and information, investors and media can contact:
Media: Hershel Berry (hberry@bplifescience.com)
Investor: PJ Kelleher (pkelleher@lifesciadvisors.com)
Opthea Limited (ASX:OPT; Nasdaq:OPT) has announced the receipt of an A$8.7 million (US$6.3 million) R&D tax credit from the Australian Taxation Office for the financial year 2021/2022. This incentive relates to costs incurred for developing its lead candidate OPT-302, which is in Phase 3 trials for wet age-related macular degeneration (wet AMD). The R&D Tax Incentive allows companies to claim 43.5% of eligible R&D expenditures. CEO Dr. Megan Baldwin stated that this funding strengthens Opthea's cash position as the company advances its clinical trials addressing unmet medical needs in retinal diseases.
Opthea Limited (NASDAQ:OPT; ASX:OPT), a biopharmaceutical company focused on innovative therapies for retinal diseases, announced that CEO Dr. Megan Baldwin will engage in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference on March 13, 2023, at 2:40 pm ET. This event can be accessed live through registration. Opthea’s lead candidate, OPT-302, is currently undergoing pivotal Phase 3 trials aimed at treating conditions like wet AMD and diabetic macular edema. The company emphasizes the risks associated with biotechnology investments, urging potential investors to seek professional advice.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced the publication of Phase 2b study results for its anti-VEGF-C/-D agent, OPT-302, in Ophthalmology. The trial, involving 366 patients with wet age-related macular degeneration (AMD), showed that OPT-302 combined with ranibizumab significantly improved visual acuity compared to ranibizumab alone. Secondary outcomes also indicated better vision gains and reduced swelling. The FDA has granted OPT-302 Fast Track Designation, facilitating its ongoing Phase 3 trials aimed at further assessment of this combination therapy.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that Dr. Megan Baldwin, CEO, will present at the SVB Leerink Global Biopharma Conference from February 14-16, 2023. Her presentation is scheduled for February 15 at 5:00 PM ET (9:00 AM AEDT). The presentation will be archived and available for viewing at Opthea's website.
Opthea is focused on developing treatments for retinal diseases like wET AMD and DME, with its lead candidate OPT-302 in pivotal Phase 3 trials. Investors should note the inherent risks in biotechnology investing.
Opthea Limited announced that Dr. Megan Baldwin, CEO, will present at the Sequire Biotechnology Conference on February 2, 2023, at 10:00 am ET (2:00 am AEDT). Interested participants can register at Sequire's website.
Opthea is focused on developing therapies for retinal diseases, particularly wet age-related macular degeneration and diabetic macular edema. Their lead product, OPT-302, is in pivotal Phase 3 trials aimed at enhancing efficacy when combined with existing treatments.
Investors are cautioned about the inherent risks in biotechnology investments, emphasizing the speculative nature of such opportunities.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced an 'Ask the Expert' conference call with Professor Jason S. Slakter on December 13, 2022. The session will cover Opthea's clinical trial programs for treating retinal diseases, specifically focusing on the management of wet AMD and the role of OPT-302. Participants can submit questions in advance. The company is developing therapies addressing unmet needs in wet age-related macular degeneration and diabetic macular edema, with OPT-302 undergoing pivotal Phase 3 trials.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced a podium presentation at the FLORetina congress in Rome from December 8-11, 2022. Dr. Caroline Baumal from Tufts University will discuss OPT-302 combination therapy in wet AMD. The presentation, titled New approach in wet-AMD treatment: Efficacy and safety of dual inhibition of VEGF-C/-D and VEGF-A with OPT-302 combination therapy, is scheduled for December 10, 2022, from 1:09 PM to 1:30 PM. Opthea is advancing its lead product, OPT-302, through Phase 3 trials targeting improved treatment outcomes for retinal diseases.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that CEO Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on November 15, 2022, at 7:25 AM GMT (6:25 PM AEDT). The presentation will be accessible via a live audio webcast for 90 days on Opthea's Investors page. The company focuses on developing therapies for retinal diseases such as wet AMD and diabetic macular edema. Its lead product, OPT-302, is currently in Phase 3 clinical trials aimed at enhancing treatment efficacy when used with anti-VEGF-A therapies.
Opthea Limited (NASDAQ:OPT), a biopharmaceutical company focused on retinal diseases, announced the appointment of Timothy E. Morris as Chief Financial Officer effective October 24, 2022. With over 25 years of experience in public biotechnology, Morris has a proven track record in raising over $2.5 billion for several companies. His expertise is expected to enhance Opthea's financial strategy as it progresses towards Phase 3 trials for its lead product, OPT-302. The company aims to improve treatment options for wet age-related macular degeneration and diabetic macular edema.
FAQ
What is the current stock price of Opthea American Depositary Shares (OPT)?
What is the market cap of Opthea American Depositary Shares (OPT)?
What does Opthea Limited specialize in?
What is OPT-302?
What stage is OPT-302 currently in?
How does Opthea fund its clinical programs?
What is the significance of VEGF-C and VEGF-D in Opthea's research?
How can investors participate in Opthea's funding offers?
What risks are associated with investing in Opthea?
Where can I find more information about Opthea’s developments?
Who can I contact for media inquiries about Opthea?
Who can I contact for investor inquiries about Opthea?
